NCT03899480 is a Phase 1 clinical trial of Haploidentical Natural Killer (NK) Cells in Hiv, sponsored by University of Minnesota.

Who is sponsoring NCT03899480?

NCT03899480 is sponsored by University of Minnesota.

What drugs are being tested in NCT03899480?

Interventions in NCT03899480: Haploidentical Natural Killer (NK) Cells.

What condition does NCT03899480 study?

NCT03899480 studies Hiv, HIV Infections, Immune Deficiency.

Is NCT03899480 still recruiting?

NCT03899480 is currently completed. Last updated 23 April 2021.

Last reviewed 2021-04-23 · How we verify

NCT03899480

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adoptive Transfer of Haploidentical NK Cells and N-803

Completed Phase 1 Last updated 23 April 2021

What this trial tests

Phase 1 trial testing Haploidentical Natural Killer (NK) Cells in Hiv in 9 participants. Completed in 1 April 2021.

Timeline

1 May 2019

Primary endpoint
1 April 2021

1 April 2021

Quick facts

Lead sponsor	University of Minnesota
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	9
Start date	1 May 2019
Primary completion	1 April 2021
Estimated completion	1 April 2021
Sites	1 location across United States

Drugs / interventions tested

Haploidentical Natural Killer (NK) Cells — full drug profile →

Conditions studied

Hiv — all drugs for Hiv →
HIV Infections — all drugs for HIV Infections →
Immune Deficiency — all drugs for Immune Deficiency →

Sponsor

University of Minnesota

Who can join

Adults 18 to 65, any sex, with Hiv or HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a pilot therapeutic study of related donor HLA-haploidentical NK-cell based therapy to determine if the treatment is safe and well-tolerated and if there is any measureable impact on virus reservoirs.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Exploring the NK cell platform for cancer immunotherapy.
Myers JA, Miller JS. · · 2021 · cited 977× · PMID 32934330 · DOI 10.1038/s41571-020-0426-7
Advances toward Curing HIV-1 Infection in Tissue Reservoirs.
Henderson LJ, Reoma LB, Kovacs JA, Nath A. · · 2020 · cited 52× · PMID 31694954 · DOI 10.1128/jvi.00375-19
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application.
Zuo W, Zhao X. · · 2021 · cited 51× · PMID 33887436 · DOI 10.1016/j.clim.2021.108727
Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy.
Wendel P, Reindl LM, Bexte T, Künnemeyer L, et al · · 2021 · cited 32× · PMID 33807011 · DOI 10.3390/cancers13061481
The role of NK cells in fighting the virus infection and sepsis.
Ma L, Li Q, Cai S, Peng H, et al · · 2021 · cited 31× · PMID 34400893 · DOI 10.7150/ijms.59898
NK cell subsets and dysfunction during viral infection: a new avenue for therapeutics?
Bjorgen JC, Dick JK, Cromarty R, Hart GT, et al · · 2023 · cited 22× · PMID 37928543 · DOI 10.3389/fimmu.2023.1267774
Natural killer cells in sepsis: Friends or foes?
Wang F, Cui Y, He D, Gong L, et al · · 2023 · cited 21× · PMID 36776839 · DOI 10.3389/fimmu.2023.1101918
Natural killer cells and their exosomes in viral infections and related therapeutic approaches: where are we?
Razizadeh MH, Zafarani A, Taghavi-Farahabadi M, Khorramdelazad H, et al · · 2023 · cited 17× · PMID 37749597 · DOI 10.1186/s12964-023-01266-2

Verify or expand the search:

Other recruiting trials for Hiv

Currently open trials in the same condition.

NCT06001814 — Mindfulness and Behavior Change to Improve Cardiovascular Health of Older People With HIV · NA · recruiting
NCT06999928 — Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV · NA · recruiting
NCT06006143 — Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 2 · Phase 2 · active not recruiting
NCT07076043 — Multi-product PrEP Delivery to Young Women Seeking Reproductive Health Services and Coverage of HIV Prevention · Phase 4 · recruiting
NCT06389565 — Change My Story Task Shifted Mental Health Intervention · NA · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03899480 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 23 April 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03899480.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing